DOI: 10.1093/bjd/ljag086.522 ISSN: 0007-0963

GD03 Improving access to diagnosis and treatment of cutaneous neglected tropical diseases: a global health perspective

Flora Alane Mar Thu-ta

Abstract

Cutaneous neglected tropical diseases (NTDs), including leprosy, Buruli ulcer and yaws, disproportionately affect populations in low-resource settings. Delayed diagnosis and limited access to dermatological care contribute to disfigurement, stigma and long-term disability. Mobile health technologies and teledermatology have emerged as potential tools to improve early detection and access to treatment. Understanding current interventions and remaining challenges is essential to guide global health strategies and reduce disease burden. This study reviews the current literature on cutaneous NTDs, focusing on strategies to improve access to diagnosis and treatment, and the role of digital and community-based interventions in low-resource settings. A narrative review was conducted using PubMed, WHO reports and grey literature from 2015–2025. Studies reporting community screening, mobile clinics, teledermatology and public health campaigns targeting cutaneous NTDs were included. Key outcomes extracted were diagnostic coverage, treatment initiation rates and implementation barriers. Community-based programmes, mobile outreach and teledermatology initiatives have improved early detection and treatment uptake. Integration of local health workers and culturally tailored education have increased engagement. Remaining challenges include inadequate resources, limited trained personnel, stigma and inconsistent follow-up. Digital tools show promise but require validation and infrastructure support to ensure sustainability. Cutaneous NTDs remain an under-recognized burden in low-resource settings. Evidence supports that community engagement, mobile clinics and teledermatology can improve diagnosis and treatment access. Future strategies should prioritize scalable, culturally sensitive interventions, strengthen local capacity and leverage technology to reduce disease burden and associated stigma globally.

More from our Archive